Metabolic issues in psychotic disorders with the focus on first-episode patients: A review

Psychiatria Danubina

Volumn 25, Issue 4, 2013, Pages 410-415

  Britvic, Dubravka ^a   Maric, Nadja P ^a,b   Doknic, Mirjana ^a,b   Pekic, Sandra ^a,b   Andric, Sanja ^a   Jasovic Gasic, Miroslava ^a,b   Popovic, Vera ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Antipsychotic agents; First episode; Metabolism; Obesity; Schizophrenia; Weight gain

Indexed keywords

NEUROLEPTIC AGENT;

CALORIC INTAKE; CLINICAL ASSESSMENT; ENERGY EXPENDITURE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; METABOLIC DISORDER; NEUROBIOLOGY; OBESITY; PHYSICAL ACTIVITY; REVIEW; SCHIZOPHRENIA; TREATMENT DURATION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; METABOLIC SYNDROME X; OBESITY; PSYCHOTIC DISORDERS; WEIGHT GAIN;

EID: 84892382154     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP et al.: The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999; 60:215-20.
2. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y et al.: Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 2005; 58:85-96.
3. rd, Dwyer DS: Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res 2001; 923:82-90.
4. Atmaca M, Kuloglu M, Tezcan E, Ustundag B: Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64:598-604.
5. Baptista T, Zárate J, Joober R, Colasante C, Beaulieu S, Páez X et al.: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004; 5:279-99.
6. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR: Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 2008; 38:103-12.
7. Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-7.
8. Carpiniello B, Pinna F, Pili R, Velluzzi F, Loviselli A: Mental disorders in obese patients with and without metabolic syndrome. Int J Psychiatry Med 2011; 42:369-75.
9. Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S et al.: Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics J 2013; 13:272-9.
10. Coll A, Challis B, Yeo G, Farooqi I, O'Rahilly S: Melanocortin receptors and energy homeostasis. Curr Opin Endocrinol and Diabetes 2005; 12:205-10.
11. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765-73.
12. Coulson M, Agius M, Zaman R: The effect of psychiatric condition and medication on the prevalence of diabetes in a psychiatric out-patient clinic: an audit. Psychiatr Danub 2012; 24:S128-9.
13. Cowley MA: Hypothalamic melanocortin neurons integrate signals of energy state. Eur J Pharmacol 2003; 480:3-11.
14. Curtis J, Henry C, Watkins A, Newall H, Samaras K, Ward PB: Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study. Early Interv Psychiatry 2011; 5:108-14.
15. De Hert M, Hanssens L, Wampers M: Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospective study of patients treated with second-generation antipsychotics. Schizophr Bull 2007; 33:560-560.
16. De Hert M, Schreurs V, Vancampfort D, VAN Winkel R: Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009; 8:15-22.
17. Doknic M, Maric NP, Britvic D, Pekic S, Damjanovic A, Miljic D et al.: Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology 2011; 94:246-54.
18. Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A et al.: The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011; 26:291-302.
19. Filakovic P, Koic O, Laufer D, Radanovic-Grguric L, Degmecic D, Pozgain I: Second generation antipsychotics and risk of diabetes type II- comparison between olanzapine and risperidone. Coll Antropol 2007; 31:1105-9.
20. Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, et al.: At risk for schizophrenic or affective psychosis? A meta-analysis of ICD/DSM diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 2012a; May 15 [Epub ahead of print].
21. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L et al.: Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012b; 69:220-9.
22. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F et al.: The psychosis high-risk state: a comprehensive state-of-the-art review. Arch Gen Psychiatry 2013; 70:107-20.
23. Fusar-Poli P, Borgwardt S, Crescini A, Deste G, Kempton MJ, Lawrie S et al.: Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev 2011a; 35:1175-85.
24. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O et al.: Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012c; 69:562-71.
25. Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin MC et al.: Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 2010; 67:683-91.
26. Fusar-Poli P & Meyer-Lindenberg A: Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET studies. Schizophr Bull 2013; 39:33-42.
27. Fusar-Poli P, Radua J, McGuire P, Borgwardt S: Neuroanatomical Maps of Psychosis Onset: Voxel-wise Meta-Analysis of Antipsychotic-Naive VBM Studies. Schizophr Bull 2012d; 38:1297-307.
28. Fusar-Poli P, Stone JM, Broome MR, Valli I, Mechelli A, McLean MA et al.: Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 2011b; 68:881-90.
29. Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G: Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22:224-35.
30. Hayes RD, Chang CK, Fernandes A, Begum A, To D, Broadbent M et al.: Associations between symptoms and all-cause mortality in individuals with serious mental illness. J Psychosom Res 2012; 72:114-9.
31. Ho BC, Andreasen N, Flaum M: Dependence on public financial support early in the course of schizophrenia. Psychiatr Serv 1997; 48:948-50.
32. Jakovljevic M, Crncevic Z, Ljubicic D, Babic D, Topic R, Saric M: Mental disorders and metabolic syndrome: a fatamorgana or warning reality? Psychiatr Danub 2007; 19:76-86.
33. Jukic V, Baric V, Culav-Sumic J, Herceg M, Majdancic Z, Werft-Cop M: The impact of novel antipsychotic drugs on quality of life among people suffering from schizophrenia. Coll Antropol 2003; 27(Suppl 1):119-24.
34. Kishi T & Elmquist JK: Body weight is regulated by the brain: a link between feeding and emotion. Mol Psychiatry 2005; 10:132-46.
35. Kohen D: Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004; 47: S64-6.
36. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-60.
37. Kozumplik O, Uzun S, Jakovljevic M: Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics. Psychiatr Danub 2010; 21:69-74.
38. Maric N, Doknic M, Pekic S, Jasovic-Gasic M, Popovic V: Weight gain associated with the treatment of psychotic disorders. Obesity Metabolism 2007; 3:88-96.
39. Maric NP, Pavlovic Z, Jasovic-Gasic M: Changes in antipsychotic prescription practice at University Hospital in Belgrade, Serbia: 2009 vs. 2004. Acta Psychiatr Scand 2011; 123:495.
40. Maric N, Popovic V, Jasovic-Gasic M, Pilipovic N, Van Os J: Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophr Res 2005; 73:351-5.
41. McGrath JJ: Variations in the incidence of schizophrenia: data versus dogma. Schizophr Bull 2006; 32:195-7.
42. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P: Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002; 22:2718-29.
43. Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S et al.: Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry 2012; 71:898-905.
44. Nonogaki K, Strack AM, Dallman MF, Tecott LH: Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998; 4:1152-6.
45. Olsen L, Hansen T, Jakobsen KD, Djurovic S, Melle I, Agartz I et al.: The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples. BMC Med Genet 2008; 9:39.
46. Peters A, Pellerin L, Dallman MF, Oltmanns KM, Schweiger U, Born J et al.: Causes of obesity: looking beyond the hypothalamus. Prog Neurobiol 2007; 81:61-88.
47. Pogge DL, Singer MB, Harvey PD: Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients. J Child Adolesc Psychopharmacol 2005; 15:901-12.
48. Protopopova D, Masopust J, Maly R, Valis M, Bazant J: The prevalence of cardiometabolic risk factors and the ten-year risk of fatal cardiovascular events in patients with schizophrenia and related psychotic disorders. Psychiatr Danub 2012; 24:307-13.
49. Redelmeier DA, Tan SH, Booth GL: The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 1998; 338:1516-20.
50. Staring AB, Van der Gaag M, Koopmans GT, Selten JP, Van Beveren JM, Hengeveld MW et al.: Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2010; 197:448-55.
51. Stone WS, Faraone SV, Su J, Tarbox SI, Van Eerdewegh P, Tsuang MT: Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am J Med Genet B Neuropsychiatr Genet 2004; 127B:5-10.
52. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D: Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010; 40:187-200.
53. Tsuang MT: Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry 1978; 35:153-5.
54. Uzun S, Kozumplik O, Sedic B: Changes in valuesof cholesterol and tryglicerides after weight lossduring treatment with aripiprazole in a patient with schizophrenia - Case report. Psychiatr Danub 2010; 22:373-6.
55. Vestri HS, Maianu L, Moellering DR, Garvey WT: Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007; 32:765-72.
56. Weiser M, Knobler H, Lubin G, Nahon D, Kravitz E, Caspi A et al.: Body mass index and future schizophrenia in Israeli male adolescents. J Clin Psychiatry 2004; 65:1546-9.
57. Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG et al.: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86:5992-5.